Research Analysts’ Recent Ratings Updates for Zevra Therapeutics (ZVRA)

Several analysts have recently updated their ratings and price targets for Zevra Therapeutics (NASDAQ: ZVRA):

• 3/16/2026 – Zevra Therapeutics is now covered by BTIG Research. They set a “buy” rating and a $23.00 price target on the stock.
• 3/14/2026 – Zevra Therapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/10/2026 – Zevra Therapeutics was upgraded by Weiss Ratings from “sell (d+)” to “hold (c+)”.
• 3/10/2026 – Zevra Therapeutics was given a new $23.00 price target by Guggenheim. They now have a “buy” rating on the stock.

Insider Transactions at Zevra Therapeutics

In related news, SVP Timothy J. Sangiovanni sold 3,000 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total transaction of $27,540.00. Following the sale, the senior vice president directly owned 29,590 shares of the company’s stock, valued at $271,636.20. This trade represents a 9.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Neil F. Mcfarlane sold 91,000 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the completion of the sale, the chief executive officer owned 364,350 shares of the company’s stock, valued at $3,417,603. This represents a 19.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 114,158 shares of company stock valued at $1,062,878. Insiders own 2.40% of the company’s stock.

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.